Pharmaceutical Industry news, analysis and insights
The latest pharmaceutical sales and marketing news
Ionis Pharmaceuticals has announced that it has entered into a new collaboration and licence agreement with Novartis, aiming to discover, develop and commercialise a novel medicine for patients with lipoprotein(a) or lp(a)-driven cardiovascular disease (CVD).
Biogen and Reata Pharmaceuticals have announced that they have entered a definitive agreement under which Biogen will acquire Reata for approximately $7.3bn, or $172.50 per share.
Alexion has announced that it has entered a definitive purchase and licence agreement with Pfizer.
Eli Lilly and Versanis Bio have announced a definitive agreement for Lilly to acquire Versanis, a private clinical-stage biopharmaceutical company focusing on the development of new medicines to treat cardiometabolic diseases.
Chinese biotechnology company LaNova medicines and UK-based pharma company AstraZeneca have announced that they have signed a global exclusive licence agreement for a preclinical stage antibody drug conjugate (ADC).
Global manufacturer for the pharmaceutical, biotech and nutraceutical markets, Lonza, has announced that it has acquired Synaffix, a biotech company focused on the commercialisation of its clinical stage technology platform for the development of antibody-drug conjugates (ADCs).
Gilead sciences has announced the acquisition of all outstanding shares of XinThera, a privately owned biotech company based in San Diego, US. This acquisition aims to strengthen Gilead’s clinical development pipeline through the addition of XinThera’s oncology and inflammation assets.
UK-based GSK has announced its plans to acquire Bellus Health, a Canadian late-stage biopharmaceutical company that focuses on treatments for refractory chronic cough (RCC). The acquisition will give GSK access to Camlipixant, Bellus’ first-in-class treatment for RCC.
Swedish Orphan Biovitrum (Sobi) has announced that it had entered into a ‘plan of merger’ with CTI Biopharma Corp (CTI), a biopharmaceutical company focused on blood-related cancers and rare diseases, by means of a tender offer valued at $1.7bn.
BioNTech and OncoC4 have entered a strategic collaboration for the co-development and commercialisation of a novel checkpoint antibody for multiple solid tumour indications. BioNTech will receive an exclusive worldwide license from oncoc4 for its anti-ctla-4 monoclonal antibody candidate, onc-392.
Pharma giant Pfizer has signed a definitive merger agreement valued at $43bn to buy biotech firm Seagen. US-based Seagen discovers, develops and commercialises cancer medicines through pioneering antibody-drug conjugates (ADCs) technology. It currently has four approved medicines in its portfolio, including three ADCs: adcetris (brentuximab vedotin) for lymphoma; padcev (enfortumab vedotin) for bladder cancers; and tivdak (tisotumab vedotin) for cervical cancer.
Théa Open Innovation (TOI) and Galimedix have announced that they have signed a licensing agreement granting TOI exclusive rights for the development and commercialisation of GAL-101, Galimedix’s treatment for dry age-related macular degeneration (AMD), glaucoma and other ophthalmic indications with high unmet medical need, in Europe, the Americas, the Middle East and Africa.